20:07 , May 18, 2018 |  BC Week In Review  |  Clinical News

Agenus shifts focus to cervical cancer from first-line NSCLC

Agenus Inc. (NASDAQ:AGEN) said in its 1Q18 earnings report that it shifted its developmental strategy to first seek approval of its checkpoint inhibitors as a second-line treatment for cervical cancer instead of as a first-line...
18:23 , Jan 12, 2018 |  BC Week In Review  |  Company News

HealthCare Royalty in vaccine royalty deal with Agenus

Agenus Inc. (NASDAQ:AGEN) will sell to HealthCare Royalty Partners (Stamford, Conn.) royalty rights on sales of vaccines from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) containing Agenus' QS-21 Stimulon adjuvant. The biotech will receive $190 million in cash,...
19:59 , Apr 21, 2017 |  BC Week In Review  |  Clinical News

AGEN2034: Ph I/II started

Agenus began an open-label, U.S. Phase I/II trial evaluating AGEN2034 in about 75 patients. The dose-escalation Phase I portion will evaluate AGEN2034 in patients with metastatic or locally advanced solid tumors. The Phase II portion...
23:22 , Feb 23, 2017 |  BC Extra  |  Company News

Agenus pointing to its checkpoint inhibitors

Agenus Inc. (NASDAQ:AGEN) is looking past the demise of its Prophage G-200 vaccine in brain cancer and pointing investors to upcoming milestones for its checkpoint inhibitor combinations. The company’s shares fell 16% on Wednesday after...